Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTX-GRT7039 in Osteoarthritis of the Knee
NCT05449132Phase 3Completed
- Sponsor
- Grünenthal GmbH
- Start
- Sep 2022
- Primary completion
- Aug 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in osteoarthritis (OA) comparing RTX-GRT7039 with Placebo (2 arms). Primary endpoint: Western Ontario and McMaster Universities Osteoarthritis Index Pain Subscale Score at 12 weeks. Started Sep 2022; status: completed.
02
Drugs
RTX-GRT7039
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05449132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05449132.